Scarica l'app Stockscreener
81.54
0.59%
-0.48
Precedente Chiudi:
$82.02
Aprire:
$81.76
Volume 24 ore:
187.28K
Relative Volume:
0.69
Capitalizzazione di mercato:
$965.15M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-0.80%
1M Prestazione:
-21.25%
6M Prestazione:
+82.66%
1 anno Prestazione:
+307.70%
Intervallo 1D:
$81.46
$85.70
Intervallo di 1 settimana:
$76.50
$85.70
Portata 52W:
$17.31
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
81.54 | 970.83M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Iniziato | Mizuho | Outperform |
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
What is the next catalyst for Palvella Therapeutics Inc.July 2025 Spike Watch & Consistent Return Investment Signals - mfd.ru
Is Palvella Therapeutics Inc. stock trending bullishWeekly Stock Analysis & Risk Controlled Stock Alerts - mfd.ru
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Published on: 2026-02-13 13:12:26 - mfd.ru
Topical statins show promise for rare skin disease in new review - MSN
Published on: 2026-02-12 04:26:17 - mfd.ru
FY2030 Earnings Forecast for PVLA Issued By HC Wainwright - Defense World
FY2030 Earnings Estimate for PVLA Issued By HC Wainwright - MarketBeat
Topical Statins Show Promise for Rare Skin Disease in New Review - MyChesCo
Notable Friday Option Activity: PVLA, XOM, RUM - Nasdaq
Palvella Therapeutics stock maintains Buy rating at Clear Street ahead of trial data - Investing.com Canada
Palvella Therapeutics (PVLA) Receives a Buy from H.C. Wainwright - The Globe and Mail
LGND: New Year Program Updates - Zacks Small Cap Research
Analysts Are Bullish on Top Healthcare Stocks: Palvella Therapeutics (PVLA), HOYA (HOCPF) - The Globe and Mail
Palvella Therapeutics, Inc. Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Por - marketscreener.com
Palvella stock rises after systematic review supports clinical potential By Investing.com - Investing.com Nigeria
Palvella stock rises after systematic review supports clinical potential - Investing.com
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porok... - Sahm
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Poroker - ChartMill
TD Cowen raises Palvella Therapeutics stock price target on BTD prospects - Investing.com Canada
Death Cross: Is CYCU in a bullish channelLayoff News & Technical Confirmation Trade Alerts - baoquankhu1.vn
Federated Hermes Inc. Takes $21.26 Million Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc Advances Late-Stage Pipeline - TradingView
Palvella Therapeutics' (PVLA) Buy Rating Reaffirmed at BTIG Research - MarketBeat
What are the risks of holding Dakota Gold Corp. Equity WarrantJuly 2025 Trends & Verified Short-Term Trading Plans - baoquankhu1.vn
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.8%Here's Why - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Pursues Targeted Immune Innovation - Kalkine Media
Published on: 2026-01-23 00:45:18 - baoquankhu1.vn
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
FOMO Trade: Does RAIN stock benefit from AI growthQuarterly Profit Report & Short-Term High Return Ideas - baoquankhu1.vn
Palvella’s QTORIN pipeline targets a breakout moment in rare skin care - MSN
Analyst Calls: Is Palvella Therapeutics Inc stock forming a cup and handle2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from BTIG Research - MarketBeat
Palvella taps veteran dermatology executive to steer medical affairs push - MSN
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December - MarketBeat
Palvella’s rare-disease pipeline gains momentum amid positive topline data - S&P Global
Pharma News: Is Palvella Therapeutics Inc a turnaround storyWeekly Investment Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Moving Averages: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aug Action: Will Palvella Therapeutics Inc stock reach all time highs in 2025 - Bộ Nội Vụ
Aspiriant LLC Acquires Shares of 5,852 Palvella Therapeutics, Inc. $PVLA - Defense World
Palvella Highlights QTORIN Pipeline and 2026 Growth Outlook - TipRanks
Palvella Therapeutics, Inc. Advances Rare Disease Therapies - TradingView — Track All Markets
Assessing Palvella Therapeutics (PVLA) Valuation After Strong One Year Returns And Conflicting Signals - Yahoo Finance
Palvella’s QTORIN Pipeline Targets a Breakout Moment in Rare Skin Care - MyChesCo
Palvella Therapeutics Joins Russell 3000 and Russell 2000 Indexes - MSN
Palvella Therapeutics provides corporate update and 2026 outlook - marketscreener.com
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):